Viking Therapeutics to Present at Biotech Showcase 2016

Jan 07, 2016, 07:30 ET from Viking Therapeutics, Inc.

SAN DIEGO, Jan. 7, 2016 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders, today announced that its chief executive officer, Brian Lian, Ph.D., will deliver a corporate presentation at the 8th Annual Biotech Showcase, being held January 11-13, 2016 in San Francisco. 

Details for this presentation are as follows:

  • Biotech Showcase 2016 – webcast available
    Time/Date:  2:30 p.m. PT on Wednesday, January 13, 2016
    Location:  Parc 55 San Francisco Hotel
    Room:  Powell Room

To access the live webcast of Viking's presentation, please visit "Webcasts & Presentations" within the News & Events section of Viking's Investors page at www.vikingtherapeutics.com. Additionally, a replay of the webcast will be available on the Viking website following the conference.

About Viking Therapeutics, Inc.
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders.  The company's research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients' lives.  Viking has exclusive worldwide rights to a portfolio of five therapeutic programs in clinical trials or preclinical studies, which are based on small molecules licensed from Ligand Pharmaceuticals, Inc.  The company's clinical programs include VK5211, an orally available, non-steroidal selective androgen receptor modulator, or SARM, in Phase 2 development for the treatment and prevention of lean body mass loss in patients who have undergone hip fracture surgery, VK2809, a small molecule thyroid beta agonist entering Phase 2 development for hypercholesterolemia and fatty liver disease, and VK0612, a first-in-class, orally available drug candidate in Phase 2 development for type 2 diabetes.  Viking is also developing novel and selective agonists of the thyroid beta receptor for adrenoleukodystrophy, as well as two earlier-stage programs targeting metabolic diseases and anemia.

 

SOURCE Viking Therapeutics, Inc.



RELATED LINKS

http://www.vikingtherapeutics.com
http://www.vikingtherapeutics.com